Welcome to SanguiBioTech GmbH
The first major milestone was the market launch of the hemoglobin-based wound spray, Granulox, via the joint venture with SastoMed GmbH. The central major project and strategic focus is the development of artificial oxygen carriers (hemoglobin hyperpolymers) as internal therapy for acute oxygen deficiency.
Granulox – out-licensed to the company SastoMed GmbH
Based on SanguiBioTech GmbH´s research and development, brought to product maturity and marketing in cooperation with Sander/Strothmann GmbH.